XML 88 R39.htm IDEA: XBRL DOCUMENT v3.6.0.2
Collaboration Agreements - AstraZeneca Agreements - Additional Information 1 (Detail) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Jul. 30, 2013
Sep. 30, 2016
Dec. 31, 2015
Jun. 30, 2015
Dec. 31, 2016
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Deferred revenue, net of current     $ 85,132   $ 106,709
AstraZeneca Agreements [Member] | U.S./RoW [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Expected upfront, non-contingent and time-based payments $ 374,000        
Development and regulatory approval milestones 550,000        
Commercial sales milestone 325,000        
Shared development costs     233,000    
Additional consideration based on net sales description         Low 20% range
Contingent payment 62,000        
AstraZeneca Agreements [Member] | U.S./RoW [Member] | FibroGen, Inc. [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Shared development costs     $ 116,500    
AstraZeneca Agreements [Member] | U.S./RoW [Member] | Development Milestones [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Receipt of development milestone payment       $ 15,000  
AstraZeneca Agreements [Member] | China [Member]          
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]          
Development and regulatory approval milestones 161,000        
Commercial sales milestone 167,500        
Proceeds from upfront payments 28,200        
Contingent payment $ 20,000        
Estimated joint development service period   2018      
Estimated joint development extended service period   2020      
Deferred revenue, net of current   $ 7,100